FindTrial
Sign In

A multicenter, non-interventional observational study to evaluate 1-year clinical outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) and Prasugrel therapy.

A multicenter, non-interventional observational study to evaluate 1-year clinical outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary interventions (PCI) and Prasugrel therapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0002356
Enrollment
3213
Registered
2017-06-13
Start date
2017-03-09
Completion date
Unknown
Last updated
2021-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Daiichi-Sankyo Korea
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) over 19 year 2) Acute coronary syndrome-Percutaneous Coronary Intervention patients treated with prasugrel according to the labeled indication 3) Patients who initiate or switch to prasugrel within 6 months after Percutaneous Coronary Intervention 4) Patients who gie voluntary written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: 1) Patients who are not simultaneously participating in interventional study administering of antiplatelet agents except prasugrel/antithrombotic agents

Design outcomes

Primary

MeasureTime frame
Net clinical events: Death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, non-CABG related TIMI major bleeding—

Secondary

MeasureTime frame
Individual incidence: Death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, non-CABG related TIMI major bleeding—

Countries

Korea, Republic of

Contacts

Public ContactYu-Hee Yeom

Seoul National University Hospital

turtree@gmail.com+82-2-2027-2677

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 12, 2026